Studies demonstrate that SII can serve as a valuable prognostic tool, potentially aiding in the stratification of patients for targeted therapies, including those involving the MCF-7 cell line, which shares moderate HER2 expression characteristic of luminal subtype A breast cancer [46,47]. The gene discussed is ERBB2; the disease is breast carcinoma.